Grundläggande statistik
| LEI | 549300JLJ5VQU2CN6016 |
| CIK | 1621443 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zynerba Pharmaceuticals Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 8, 2024 |
ZYNE / Zynerba Pharmaceuticals Inc / Beryl Capital Management LLC Passive Investment SC 13G/A 1 zyne13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zynerba Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98986X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37526 Zynerba Pharmaceuticals, Inc. (Exact name of registrant as specifi |
|
| October 11, 2023 |
CERTIFICATE OF INCORPORATION ZYNERBA PHARMACUETICALS, INC. Exhibit 3.1 CERTIFICATE OF INCORPORATION OF ZYNERBA PHARMACUETICALS, INC. 1. Name. The name of the Corporation is Zynerba Pharmaceuticals, Inc. 2. Registered Office and Agent. The address of the registered office of Zynerba Pharmaceuticals, Inc. in the State of Delaware is c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801 |
|
| October 11, 2023 |
Exhibit (a)(5)(C) HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11. |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Zynerba Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Xylophone Acquisition Corp. a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. (Names of Filing Persons (identifying status |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-264966 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-264966 UNDER THE SECURITIES ACT OF 1933 Zynerba Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
ZYNERBA PHARMACEUTICALS, INC. a Delaware Corporation AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Exhibit 3.2 ZYNERBA PHARMACEUTICALS, INC. a Delaware Corporation AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Page Article 1 OFFICES 1 Section 1.1 Offices 1 Section 1.2 Form of Records 1 Article 2 STOCKHOLDERS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 1 Section 2.3 Special Meetings 1 Section 2.4 Notice of Meetings 1 Section 2.5 Conduct of Meetings 2 Section 2.6 Adjournments 2 |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37526 26-0389433 (State or other jurisdiction of incorporation) (Com |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company) Zynerba Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 11, 2023 As filed with the Securities and Exchange Commission on October 11, 2023 No. 333-272805 No. 333-270891 No. 333-263128 No. 333-256028 No. 333-237051 No. 333-230182 No. 333-223597 No. 333-216967 No. 333-216968 No. 333-207973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-272805 Post-Effective Amendment |
|
| October 5, 2023 |
Exhibit (a)(1)(G) Notice of Guaranteed Delivery to Tender of Shares of Common Stock Of ZYNERBA PHARMACEUTICALS, INC. |
|
| October 5, 2023 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF MERGER Exhibit (d)(5) EXECUTION VERSION AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 (this “Amendment”) dated as of October 4, 2023, to the Agreement and Plan of Merger, dated as of August 14, 2023 (the “Agreement”), by and among: Harmony Biosciences Holdings, Inc., a Delaware corporation (“Parent”); Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Zynerba Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Xylophone Acquisition Corp. a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. (Names of Filing Persons (identifying statu |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company) Zynerba Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of |
|
| October 4, 2023 |
Exhibit (a)(5)(N) Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions DEVON, Pa. |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company) Zynerba Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of |
|
| September 29, 2023 |
Exhibit (a)(5)(M) Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 DEVON, Pa. |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Zynerba Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Xylophone Acquisition Corp. a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. (Names of Filing Persons (identifying statu |
|
| September 27, 2023 |
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Exhibit 99.(a)(5)(B) HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. PLYMOUTH MEETING, Pa, September 27, 2023 — In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiratio |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company) Zynerba Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company) Zynerba Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Zynerba Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Xylophone Acquisition Corp. a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. (Names of Filing Persons (identifying statu |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company) Zynerba Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of |
|
| September 14, 2023 |
Goodwin Procter LLP One Commerce Square 2005 Market Street, 32nd Floor Philadelphia, PA 19103 goodwinlaw. |
|
| September 5, 2023 |
ZYNE / Zynerba Pharmaceuticals Inc / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zynerba Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98986X109 (CUSIP Number) August 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| August 29, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37526 26-0389433 (State or other jurisdiction of incorporation) (Comm |
|
| August 28, 2023 |
Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| August 28, 2023 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of ZYNERBA PHARMACEUTICALS, INC. |
|
| August 28, 2023 |
AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit (e) (12) AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) to the Employment Agreement by and between Zynerba Pharmaceuticals, Inc. |
|
| August 28, 2023 |
CONFIDENTIALITY AND NONDISCLOSURE AGREEMENT Exhibit (d)(4) CONFIDENTIALITY AND NONDISCLOSURE AGREEMENT THIS CONFIDENTIALITYANDNONDISCLOSURE AGREEMENT (this“Agreement”) is entered into as of this 17th day of November, 2021, by and between Harmony Biosciences, LLC “Harmony”), a Delaware limited liability company, and Zynerba Pharmaceuticals, Inc. |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Xylophone Acquisition Corp. a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.001 par |
|
| August 28, 2023 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ZYNERBA PHARMACEUTICALS, INC. |
|
| August 28, 2023 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ZYNERBA PHARMACEUTICALS, INC. |
|
| August 28, 2023 |
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT Exhibit (d)(2) FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2023 (this “Agreement”), is entered into by and between Harmony Biosciences Holdings, Inc. |
|
| August 28, 2023 |
AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit (e) (18) AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) to the Employment Agreement by and between Zynerba Pharmaceuticals, Inc. |
|
| August 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO Zynerba Pharmaceuticals, Inc. |
|
| August 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company) Zynerba Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class |
|
| August 28, 2023 |
Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ZYNERBA PHARMACEUTICALS, INC. |
|
| August 24, 2023 |
ZYNE / Zynerba Pharmaceuticals Inc / Harmony Biosciences Holdings, Inc. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ZYNERBA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 98986X109 (CUSIP Number) Christian Ulrich General Counsel and Corporate Secretary Harmony Biosciences Holdings, Inc. 630 W. Germantown Pike, Suite 215 Plymouth Meet |
|
| August 24, 2023 |
EX-99.3 2 brhc20057945ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them |
|
| August 14, 2023 |
Exhibit 99.1 HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Lead asset in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 HARMONY BIOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS E |
|
| August 14, 2023 |
Exhibit 99.2 HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Lead asset in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Zynerba Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Xylophone Acquisition Corp. a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.001 par |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ZYNERBA PHARMACEUTICALS, INC. (Name of Subject Company) ZYNERBA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 98986X109 (CUSIP Numb |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.3 14 August 2023 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is in |
|
| August 14, 2023 |
Exhibit 10.2 INCENTIVE STOCK OPTION AGREEMENT UNDER THE ZYNERBA PHARMACEUTICALS, INC. 2023 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share:$ Grant Date: Expiration Date: Pursuant to the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Zynerba Pharmaceuticals, Inc. (the “Compan |
|
| August 14, 2023 |
Exhibit 10.6 RESTRICTED STOCK AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE ZYNERBA PHARMACEUTICALS, INC. 2023 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Shares: Grant Date: Pursuant to the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, Zynerba Pharmaceuticals, Inc. (the “Company”) hereby grants a Restricted S |
|
| August 14, 2023 |
Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) to the Employment Agreement by and between Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Armando Anido (“Executive”), originally dated September 4, 2014 and amended on October 2, 2014, and again on August 30, 2019, (the “Employment Agreement”), is made as of August 14, 2023 (the “Eff |
|
| August 14, 2023 |
Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan Exhibit 10.1 ZYNERBA PHARMACEUTICALS, INC. 2023 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Zynerba Pharmaceuticals, Inc. (the “Compa |
|
| August 14, 2023 |
Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) to the Employment Agreement by and between Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and James Fickenscher (“Executive”), originally dated August 11, 2016 and amended on August 30, 2019, (the “Employment Agreement”), is made as of August 14, 2023 (the “Effective Date”). W I T N E |
|
| August 14, 2023 |
Exhibit 10.3 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER ZYNERBA PHARMACEUTICALS, INC. 2023 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share:$ Grant Date: Expiration Date: Pursuant to the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Zynerba Pharmaceutic |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ZYNERBA PHARMACEUTICALS, INC. (Name of Subject Company) ZYNERBA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 98986X109 (CUSIP Numb |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.6 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is intended to suppo |
|
| August 14, 2023 |
Exhibit 99.2 HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Lead asset in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.5 14 August 2023 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is in |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.7 14 August 2023 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is in |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.2 14 August 2023 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is in |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.4 14 August 2023 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is in |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.1 14 August 2023 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is in |
|
| August 14, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among HARMONY BIOSCIENCES HOLDINGS, INC., XYLOPHONE ACQUISITION CORP. and ZYNERBA PHARMACEUTICALS, INC. Dated as of August 14, 2023 NO AGREEMENT, ORAL OR WRITTEN, REGARDING OR RELATING TO ANY OF THE MATTERS COVERED BY THIS DOCUMENT HAS BEEN ENTERED INTO BETWEEN THE PARTIES. THIS DOCUMENT IS INTENDED SOLELY TO FAC |
|
| August 14, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among HARMONY BIOSCIENCES HOLDINGS, INC., XYLOPHONE ACQUISITION CORP. and ZYNERBA PHARMACEUTICALS, INC. Dated as of August 14, 2023 NO AGREEMENT, ORAL OR WRITTEN, REGARDING OR RELATING TO ANY OF THE MATTERS COVERED BY THIS DOCUMENT HAS BEEN ENTERED INTO BETWEEN THE PARTIES. THIS DOCUMENT IS INTENDED SOLELY TO FACILITATE DISCUSSIONS |
|
| August 14, 2023 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) to the Employment Agreement by and between Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Terri Sebree (“Executive”), originally dated October 2, 2014 and amended on August 30, 2019, (the “Employment Agreement”), is made as of August 14, 2023 (the “Effective Date”). W I T N E S S E |
|
| August 14, 2023 |
80 W. Lancaster Avenue, Suite 300| Devon, PA 19333 | 484-581-7505 | www.zynerba.com Exhibit 99.8 14 August 2023 Good day, As announced this morning in a joint press release (attached), Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (“Zynerba”). The acquisition is in |
|
| August 14, 2023 |
Exhibit 10.5 RESTRICTED STOCK AWARD AGREEMENT UNDER THE ZYNERBA PHARMACEUTICALS, INC. 2023 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Shares: Grant Date: Pursuant to the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, Zynerba Pharmaceuticals, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 14, 2023 |
Exhibit 99.1 Execution Version TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”) is entered into as of August 14, 2023, by and among Harmony Biosciences Holdings, Inc., a Delaware corporation (“Parent”), Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and [●] (“Stockholder”). Recitals A.Parent, Merger Sub a |
|
| August 14, 2023 |
Exhibit 99.1 Execution Version TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”) is entered into as of August 14, 2023, by and among Harmony Biosciences Holdings, Inc., a Delaware corporation (“Parent”), Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and [●] (“Stockholder”). Recitals A. Parent, |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37526 26-0389433 (State or other jurisdiction of incorporation) (Comm |
|
| August 14, 2023 |
Exhibit 99.2 Harmony Biosciences Proposed Acquisition of Zynerba Pharmaceuticals, Inc. Conference Call August 14, 2023 Corporate Speakers • Luis Sanay; Harmony Biosciences; Head of Investor Relations • Jeffrey Dayno; Harmony Biosciences; President and Chief Executive Officer • Sandip Kapadia; Harmony Biosciences; Chief Financial Officer • Kumar Budur; Harmony Biosciences; Chief Medical Officer Par |
|
| August 14, 2023 |
Exhibit 10.4 NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER ZYNERBA PHARMACEUTICALS, INC. 2023 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share:$ Grant Date: Expiration Date: Pursuant to the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Zynerba Pharmac |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| June 21, 2023 |
As filed with the Securities and Exchange Commission on June 21, 2023 As filed with the Securities and Exchange Commission on June 21, 2023 Registration No. |
|
| June 21, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zynerba Pharmaceuticals, Inc. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37526 26-0389433 (State or other jurisdiction of incorporation) (Commis |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37526 26-0389433 (State or other jurisdiction of incorporation) (Commiss |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 15, 2023 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash equivalents at March 31, 2023; Cash runway to mid-year 2024 Proposal for a reverse stock split is on |
|
| May 15, 2023 |
Exhibit 99.2 © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next - Generation Transdermal Cannabinoid Therapeutics May 2023 Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among othe |
|
| May 4, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37526 26-0389433 (State or other jurisdiction of incorporation) (Commiss |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| April 21, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 10, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| March 28, 2023 |
Up to $11,182,507 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-264966 PROSPECTUS SUPPLEMENT (To the Prospectus dated June 10, 2022) Up to $11,182,507 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated June 10, 2022, filed with the Securities and Exchange Commission as a part of our Registration Statement on Form S-3 (File No. 333-264966) on May 16, 2022, |
|
| March 28, 2023 |
Filing Fee Table (filed herewith). EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zynerba Pharmaceuticals, Inc. |
|
| March 28, 2023 |
Exhibit 99.2 © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next - Generation Transdermal Cannabinoid Therapeutics March 2023 Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among ot |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
List of subsidiaries of the registrant (filed herewith). Exhibit 21.1 Subsidiaries of Zynerba Pharmaceuticals, Inc. Subsidiary Jurisdiction of Incorporation Zynerba Pharmaceuticals Pty Ltd Australia |
|
| March 28, 2023 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug designation for cannabidiol, the active ingredient in Zygel, in 22q11.2 dele |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37526 Zynerba Phar |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizati |
|
| January 9, 2023 |
EX-99.1 2 tm232480d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. January 2023 Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other thing |
|
| December 21, 2022 |
Exhibit 99.2 ? 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. December 2022 Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other things relate to the future operations, opportun |
|
| December 21, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel? in Fragile X Syndrome RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the ?Tripledemic? (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of re |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| December 5, 2022 |
Exhibit 99.2 ? 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. December 2022 Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other things relate to the future operations, opportun |
|
| December 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 5, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizat |
|
| December 5, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology Zygel? achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON, Pa |
|
| November 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 15, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 15, 2022 |
Exhibit 99.1 ? 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQZYNE Advancing Science.Improving Connections.Next-Generation Transdermal Cannabinoid TherapeuticsNovember 2022 Forward-Looking StatementsThe statements in this presentation may include forward-looking statements within the meaning of the private securities litigation reform act of 1995. These statements, among other thing |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 14, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel? in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024 DEVON, Pa., November 1 |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 4, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizat |
|
| September 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 13, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 13, 2022 |
Exhibit 99.1 ? 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next - Generation Transdermal Cannabinoid Therapeutics September 2022 Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, amon |
|
| August 10, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel? in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company foc |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2022 |
Exhibit 99.2 ? 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next - Generation Transdermal Cannabinoid Therapeutics August 2022 Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among o |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizati |
|
| July 21, 2022 |
Exhibit 10.2 Certain portions of this document have been omitted pursuant to Item 601(a)(6) of Regulation S-K and, where applicable, have been marked with “[***]” to indicate where omissions have been made. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 21, 2022, is entered into by and between ZYNERBA PHARMACEUTICALS, INC., a Delaware corporat |
|
| July 21, 2022 |
Exhibit 10.1 Certain portions of this document have been omitted pursuant to Item 601(a)(6) of Regulation S-K and, where applicable, have been marked with ?[***]? to indicate where omissions have been made. PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the "Agreement"), dated as of July 21, 2022, is made by and between ZYNERBA PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and LINCOL |
|
| July 21, 2022 |
Up to $20,000,000 of Shares of Common Stock and 347,222 Shares of Common Stock ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-264966 PROSPECTUS SUPPLEMENT (To Prospectus dated June 10, 2022) Up to $20,000,000 of Shares of Common Stock and 347,222 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $20,000,000 of shares of our common stock that we may sell to Lincoln Park Capital Fund, LLC (?Lincoln Park?), from time to time pu |
|
| July 21, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 21, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 22, 2022 |
Exhibit 99.2 © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. Next-Generation Transdermal Cannabinoid Therapeutics June 2022 Forward-Looking Statements The statements in this presentation may include forward-looking statements within the meaning of the private securities litigation reform act of 1995. These statements, among other thin |
|
| June 22, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel? in 22q11.2 Deletion Syndrome ? The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments ? ? Safety data reinforce excellent tolerability profile of Zygel ? ? Company will focus resources on FXS and |
|
| June 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 8, 2022 |
Zynerba Pharmaceuticals, Inc. 80 W. Lancaster Avenue, Suite 300 Devon, PA 19333 June 8, 2022 Zynerba Pharmaceuticals, Inc. 80 W. Lancaster Avenue, Suite 300 Devon, PA 19333 June 8, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Michael Davis Re: Zynerba Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 16, 2022 (File No. 333-264966) Ladies and Gentlemen: Pursuant to Rule 461 unde |
|
| June 1, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Presents Data on Zygel? at the American Society of Clinical Psychopharmacology Annual Meeting ? Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial ? ? Oral presentation demonstrates long-term safety and potential effectiveness of Zygel in children and adolescents with Fragile X syndrome ? DEVON, Pa., June 1, 2022 ? Zyne |
|
| June 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization) |
|
| May 16, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights ? Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel? in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 ? ? Topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) expected mid-year 2022 ? |
|
| May 16, 2022 |
Form S-3 (File No. 333-264966) As filed with the Securities and Exchange Commission on May 16, 2022 Registration No. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zynerba Pharmaceuticals, Inc. |
|
| May 16, 2022 |
Exhibit 99.2 Corporate Overview May 2022 Forward - Looking Statements 2 ? 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - LOOKIN |
|
| May 16, 2022 |
EXHIBIT 4.4 ZYNERBA PHARMACEUTICALS, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. OTHER DEFINITIONS 5 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 5 1.4. RULES OF CONSTRUCTION 6 ARTICLE 2 THE SECURITIES 6 2.1. ISSUABLE IN SERIES 6 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 7 2. |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization) |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| April 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . ? Commission file number: 001-37526 ? Zynerb |
|
| March 1, 2022 |
Exhibit 99.2 Corporate Overview March 2022 Forward - Looking Statements 2 ? 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - LOOK |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| March 1, 2022 |
List of subsidiaries of the registrant (filed herewith). Exhibit 21.1 ? Subsidiaries of Zynerba Pharmaceuticals, Inc. ? Subsidiary Jurisdiction of Incorporation Zynerba Pharmaceuticals Pty Ltd Australia ? ? ? |
|
| March 1, 2022 |
EX-FILING FEES 4 tm227886d1ex-filingfees.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zynerba Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit |
|
| March 1, 2022 |
Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (filed herewith). Exhibit 10.8 CONFIDENTIAL ? Board of Directors Compensation Policy ? This policy sets forth the compensation for non-employee members of the Board of Directors of Zynerba Pharmaceuticals, Inc. (?Company?) from and after January 1, 2022. The Board of Directors may change this policy at any time. Compensation Element Amount ? Paid or Granted Board of Directors: ? Director Retainer ? Lead Independent |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights ? European Commission granted orphan drug designation for ZygelTM in Fragile X syndrome (FXS) ? ? Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS; topline results expected second-half 2023 ? ? Completed enrollment in Phase |
|
| March 1, 2022 |
CONFIDENTIAL Exhibit 10.3(A) ? EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of February 14, 2022 (the ?Effective Date?) by and between Zynerba Pharmaceuticals, Inc., a Delaware corporation (the ?Employer?) and Albert P. Parker, II (the ?Employee?). Recitals WHEREAS, the Employer desires to employ the Employee and the Employee desires to be employed |
|
| February 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| February 28, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel? in 22q11.2 Deletion Syndrome ? Topline data from Phase 2 INSPIRE trial expected mid-year 2022 ? DEVON, Pa., February 28, 2022 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric di |
|
| February 28, 2022 |
Exhibit 99.2 Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel ? in Fragile X Syndrome ? Provides 10-year market exclusivity in EU upon regulatory approval ? DEVON, Pa., February 28, 2022 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neurop |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* Zynerba Pharmaceuticals Inc (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 98986X109 (CUSIP Number) February 11, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 4, 2022 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizati |
|
| January 4, 2022 |
Corporate Overview January 2022 Exhibit 99.2 Corporate Overview January 2022 Forward - Looking Statements 2 ? 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - LO |
|
| January 4, 2022 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE ? Company plans to focus development of Zygel in FXS, ASD and 22Q ? ? Company plans to initiate Phase 3 trial with Zygel? in ASD in the second half of 2022 ? ? Zynerba to hold conference call tomorrow, January 5 2022 at 9:00 a.m. ET ? DEVON, Pa., January 4, 2022 ? Zynerba Pharmaceuticals, Inc. (Na |
|
| November 22, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 22, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 22, 2021 |
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™ Exhibit 99.1 Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel? DEVON, Pa., November 22, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled ?Treatment of |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 15, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| November 15, 2021 |
Corporate Overview November 2021 Exhibit 99.2 Corporate Overview November 2021 Forward - Looking Statements 2 ? 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - L |
|
| November 15, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights ? Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel? in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 ? ? Cash runway well into the first half of 2024; $75.6 million at September 30, 2021 ? DEVON, Pa., November 15, 2021 ? Zynerba Pharmace |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 13, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel? in Fragile X Syndrome Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., September 13, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced tra |
|
| September 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 13, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 13, 2021 |
Corporate Overview September 2021 Exhibit 99.2 Corporate Overview September 2021 Forward - Looking Statements 2 ? 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - |
|
| September 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 9, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| September 9, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel? in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 DEVON, Pa., September 9, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therap |
|
| September 7, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open- Label Study of Zygel? in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open DEVON, Pa., September 7, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ne |
|
| September 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| August 9, 2021 |
? Amended and Restated BYLAWS OF ZYNERBA PHARMACEUTICALS, INC. ? Adopted: July 29, 2021 1.STOCKHOLDERS 1.1.Annual Meeting. An annual meeting of the stockholders of Zynerba Pharmaceuticals, Inc. (the ?Corporation?) shall be held in each calendar year, on such date and at such time as may be fixed by the board of directors of the Corporation (the ?Board?), for the purpose of electing directors in ac |
|
| August 9, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights ? On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel? in patients with FXS, in the third quarter of 2021 ? ? Positive feedback from FDA clarifies potential path forward in ASD ? ? Cash runway well into the first half of 2024; $85.8 million at June 30, 2021 ? DEVON, Pa., |
|
| August 9, 2021 |
Corporate Overview August 2021 Exhibit 99.2 Corporate Overview August 2021 Forward - Looking Statements 2 ? 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - LOO |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| August 9, 2021 |
CONFIDENTIAL Zynerba Pharmaceuticals, Inc. ZYNERBA PHARMACEUTICALS, INC. 2014 OMNIBUS INCENTIVE COMPENSATION PLAN RESTRICTED STOCK GRANT This RESTRICTED STOCK GRANT AGREEMENT (this ?Agreement?), dated as of (the ?Date of Grant?), is delivered by Zynerba Pharmaceuticals, Inc. (the ?Company?), to (the ?Grantee?). RECITALS A.The Zynerba Pharmaceuticals, Inc. 2014 Omnibus Incentive Compensation Plan, |
|
| August 5, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| July 30, 2021 |
Certificate of Amendment to the Amended and Restated Bylaws of Zynerba Pharmaceuticals, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT to the AMENDED AND RESTATED BYLAWS of ZYNERBA PHARMACEUTICALS, INC. I, Suzanne M. Hanlon, in my capacity as Secretary of Zynerba Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby certify that the Amended and Restated Bylaws (the ?Bylaws?) of the Company were amended by a resolution adopted by the board of directors of the Company on July 29, |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 29, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def |
|
| July 14, 2021 |
Exhibit 99.1 Corporate Overview July 2021 Forward - Looking Statements 2 ? 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - LOOKI |
|
| July 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 14, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 30, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting - 49% of shares voted, quorum not established to hold annual meeting ? - Meeting scheduled to reconvene August 3, 2021 at 9:00 AM EDT ? - Company strongly encourages stockholders holding unvoted proxies to cast their votes - DEVON, Pa., June 30, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| June 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| June 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization) |
|
| June 9, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting - 46.4% of shares voted, quorum not established to hold annual meeting ? - Meeting scheduled to reconvene June 29, 2021 at 9:00 AM EDT ? - Company strongly encourages stockholders holding unvoted proxies to cast their votes - DEVON, Pa., June 9, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* Zynerba Pharmaceuticals Inc (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 98986X109 (CUSIP Number) May 28, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization) |
|
| May 26, 2021 |
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.2 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE ZYNERBA PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 1:20-cv-00557-CFC NOTICE TO CURRENT ZYNERBA SHAREHOLDERS OF PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF DERIVATIVE ACTION TO: ALL OWNERS OF ZYNERBA PHARMACEUTICALS, INC. (?ZYNERBA? OR THE ?COMPANY?) STOCK (TICKER SYMBOL: ZYNE). PLEASE READ TH |
|
| May 26, 2021 |
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE ZYNERBA PHARMACEUTICALS, INC. Lead Case No. 1:20-cv-00557-CFC DERIVATIVE LITIGATION THIS STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation and Agreement of Settlement (the ?Stipulation?), dated April 28, 2021, is made and entered into by and among the following Parties (as defined herein), each by and throug |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization) |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2021 |
As filed with the Securities and Exchange Commission on May 12, 2021 As filed with the Securities and Exchange Commission on May 12, 2021 Registration No. |
|
| May 12, 2021 |
? Zynerba Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement May 11, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 ? Canaccord Genuity LLC 99 High Street, Suite 1200 Boston, Massachusetts 02110 ? H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 ? Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 2 |
|
| May 12, 2021 |
Up to $75,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-233038 PROSPECTUS SUPPLEMENT (To Prospectus dated August 13, 2019) Up to $75,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the sales agreement, with Cantor Fitzgerald & Co., or Cantor, Canaccord Genuity LLC, or Canaccord Genuity, H.C. Wainwright & Co., LLC, or H.C. Wainwright & Co., and Ladenburg T |
|
| May 12, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights ? RECONNECT, a confirmatory pivotal trial of Zygel? in patients with FXS, expected to be initiated in the third quarter of 2021 ? ? Cash runway well into first half 2024; $93.1 million at March 31, 2021 ? DEVON, Pa., May 12, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Zynerba Pharmaceuticals Inc (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 98986X109 (CUSIP Number) May 10, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization) |
|
| May 5, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel? in Fragile X Syndrome - Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 - - Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET - DEVON, Pa., May 5, 2021 ? Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal |
|
| May 5, 2021 |
Zynerba Pharmaceuticals, Inc. Presentation. Exhibit 99.2 Corporate Overview May 2021 Forward-Looking Statements THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS, AMONG OTHER THINGS RELATE TO THE FUTURE OPERATIONS, OPPORTUNITIES OR FINANCIAL PERFORMANCE OF ZYNERBA PHARMACEUTICALS, INC. WE MAY, IN SOME CASES, USE TERMS SUCH A |
|
| April 21, 2021 |
DEF 14A 1 tm2111207-2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def |
|
| April 1, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Zynerba Pharmaceuticals Inc (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 98986X109 (CUSIP Number) March 9, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . ? Commission file number: 001-37526 ? Zyner |
|
| March 10, 2021 |
LEASE AMENDMENT #4 ? THIS LEASE AMENDMENT #4 (?Amendment #4?) is entered into as of the 1st day of March 2021, by and between PROVCO DEVON, L. |
|
| March 10, 2021 |
List of subsidiaries of the registrant (filed herewith). Exhibit 21.1 ? Subsidiaries of Zynerba Pharmaceuticals, Inc. ? Subsidiary Jurisdiction of Incorporation Zynerba Pharmaceuticals Pty Ltd Australia ? ? ? |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2021 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizatio |
|
| March 10, 2021 |
Exhibit 99.1 Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights DEVON, Pa., March 10, 2021 – Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full |
|
| March 10, 2021 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zynerba Pharmaceuticals, Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The Company?s common stock, $0.001 par value per share (?Common Stock?) is registered under Secti |
|
| March 10, 2021 |
LEASE AMENDMENT #3 ? THIS LEASE AMENDMENT #3 (?Amendment #3?) is entered into as of the 11th day of November 2019, by and between PROVCO DEVON, L. |
|
| March 10, 2021 |
Exhibit 99.2 Corporate Overview March 2021 Forward - Looking Statements 2 ? 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - LOOK |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Zynerba Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 98986X109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Zynerba Pharmaceuticals Inc (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 98986X109 (CUSIP Number) January 7, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| December 17, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiza |
|
| December 17, 2020 |
Corporate Overview December 2020 Exhibit 99.2 Corporate Overview December 2020 Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - L |
|
| December 17, 2020 |
Exhibit 99.1 Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome - Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial - - Conference Call and Webcast Today, December 17, 2020 at 8:30 am ET - DEVON, Pa., December 17, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) |
|
| December 4, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 4, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizat |
|
| December 4, 2020 |
Exhibit 99.1 Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) - New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 - - Zygel™ Improves the Profound Sleep Disturbance Often Experienced by Developme |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Zynerba Pharmaceuticals Inc (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 98986X109 (CUSIP Number) November 13, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 9, 2020 |
Corporate Overview November 2020 Exhibit 99.2 Corporate Overview November 2020 Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - L |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizat |
|
| November 9, 2020 |
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights Exhibit 99.1 Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights DEVON, Pa., November 9, 2020 - Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2020 |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 15, 2020 |
Exhibit 99.2 New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting DEVON, Pa., October 15, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-pro |
|
| October 15, 2020 |
EX-99.1 2 tm2032919d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting DEVON, Pa., October 15, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovativ |
|
| October 15, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizat |
|
| September 17, 2020 |
Exhibit 99.1 Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome DEVON, Pa., September 17, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administr |
|
| September 17, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 17, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 14, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organiz |
|
| September 14, 2020 |
Zynerba Pharmaceuticals Provides Update on Recent Milestones Exhibit 99.1 Zynerba Pharmaceuticals Provides Update on Recent Milestones - Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully Methylated FMR1 Gene - - Newly Issued FXS Patent Supplements Intellectual Property Protection – - FDA Suggests Pursuing Individual Syn |
|
| September 14, 2020 |
Corporate Overview September 2020 Exhibit 99.2 Corporate Overview September 2020 Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - |
|
| August 10, 2020 |
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights Exhibit 99.1 Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights DEVON, Pa., August 10, 2020 - Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2020, an |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8–K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organizati |
|
| August 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 10, 2020 |
Corporate Overview August 2020 Exhibit 99.2 Corporate Overview August 2020 Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD - LOO |
|
| July 22, 2020 |
Exhibit 99.1 Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup - New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes - DEVON, Pa., July 22, 2020 – Zynerba Pharmaceuticals, |
|
| July 22, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8–K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 22, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8–K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2020 ZYNERBA PHARMACEUTICALS, INC. (Exact Name of Issuer as Specified in Charter) Delaware 001-37526 26-0389433 (State or Other Jurisdiction of Incorporation or Organization |
|
| June 30, 2020 |
Exhibit 99.1 Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome - Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set - - Achieved Statistical Significance on Primary Endpoint (p=0.020) in Pre-Planned Ad Hoc Analysis of Patients with Full Methylation of the FMR1 Gene Compri |
